Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sovaldi, Oral, Interferon-Free Treatment, Approved for Chronic HCV Infection in Japan: Gilead Sciences
March 27, 2015
- Xtandi Significantly Extends OS, Lowers Risk of Death by 23%
March 26, 2015
- Santen Ups FY2014 Financial Outlook on Merck Asset Acquisition
March 26, 2015
- Sun Pharma Completes Merger with Ranbaxy; Daiichi Sankyo Owns 9% Share in Combined Firm
March 26, 2015
- Yoshiki Ito to Lead Merged Entity of Allergan, Actavis in Japan
March 25, 2015
- 3-Bracket Pricing Rule for Generics Should Be Defended: Sawai Chairman
March 25, 2015
- Takeda to Collaborate with ImmunoGen for ADC Technology
March 25, 2015
- Investigational Duchenne Muscular Dystrophy Drug Shows Favorable Results: Nippon Shinyaku, NCNP
March 25, 2015
- AZ Looks to Lead Industry in Immuno-Oncology Arena: Oncology Head
March 24, 2015
- Opdivo Wins South Korean Approval: Ono
March 24, 2015
- Takeda to Set Up Japan Oncology, Vaccine Business Units as Part of Corporate Reorganization
March 24, 2015
- Merck KGaA Gauging Regional Priorities for PD-L1 Inhibitor Development: Exec
March 24, 2015
- Amgen Astellas Seeks Japan Approval of PCSK9 Inhibitor
March 23, 2015
- Pfizer Japan Voluntarily Recalls Generic Gemcitabine
March 23, 2015
- Opicapone Reduces Off-Time by 2 Hours in Parkinson’s Disease Patients as Add-On to Levodopa: Ono
March 20, 2015
- Daiichi Sankyo, AZ to Copromote Constipation Treatment Movantik in US
March 20, 2015
- Astellas Files Kiklin to Treat Non-Dialysis CKD Patients
March 18, 2015
- MSD Revving Up Detailing on Rotavirus, Hepatitis B Vaccines, Eyes Public Immunization Program
March 18, 2015
- Alirocumab Meets Primary Efficacy Endpoint in PIII Study: Sanofi
March 17, 2015
- Minophagen Seeks Approval for CTCL Treatment
March 17, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…